Generation Bio Co. (GBIO)
| Previous Close | 5.14 |
| Open | 5.19 |
| Bid | 4.00 x 1300 |
| Ask | 5.50 x 1200 |
| Day's Range | 4.99 - 5.44 |
| 52 Week Range | 3.96 - 34.61 |
| Volume | |
| Avg. Volume | 417,796 |
| Market Cap | 308.451M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.10 |
| Earnings Date | Mar 16, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 22.25 |
- Simply Wall St.
Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Zacks
Generation Bio Co. (GBIO) Reports Q1 Loss, Lags Revenue Estimates
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -17.31% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Generation Bio Reports Business Highlights and First Quarter 2022 Financial Results
Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines Cash balance of $337.0M expected to fund operations into 2024 CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and first quarter 2022 financial results. “We are making s
